Featured Research

from universities, journals, and other organizations

PSA Remains Best Indicator Of Prostate Cancer Progression

Date:
September 18, 2005
Source:
Johns Hopkins Medical Institutions
Summary:
Despite recent claims by some urologists that measuring the blood protein prostate-specific antigen (PSA) may not be effective in predicting risk of prostate cancer, a Johns Hopkins study of more than 2,000 men confirms that PSA remains the best measure of the likelihood of cancer recurrence after surgery.

Despite recent claims by some urologists that measuring the blood proteinprostate-specific antigen (PSA) may not be effective in predicting risk ofprostate cancer, a Johns Hopkins study of more than 2,000 men confirms thatPSA remains the best measure of the likelihood of cancer recurrence aftersurgery.

Related Articles


Results of the study, published in the October issue of The Journal ofUrology, demonstrated that men with high PSA levels prior to prostateremoval surgery were significantly more likely to have advanced clinicalstages of cancer, evidence of higher grade cancers in surgically removedtissue, and spread of cancer cells beyond the prostate. In addition,increasing PSA was significantly associated with increased risk of cancerrecurrence after surgery, even in men with lower PSA levels prior to surgery.

The study was led by Stephen J. Freedland, M.D., clinical instructor ofurology, and Alan W. Partin, M.D., Ph.D., professor and chair of urology atJohns Hopkins' Brady Urological Institute.

"In our study, PSA levels measured before prostate removal surgery weresignificantly associated with the risk of recurrent cancer after surgery,"Freedland says. "These data support the notion that PSA remains the bestavailable prostate cancer tumor marker. It certainly suggests that the PSAera is alive and well."

PSA is a protein produced by cells of the prostate gland. Prostate cancercan increase PSA, so the higher the PSA level, the greater the likelihoodthat a patient has prostate cancer. Also, higher PSA values generallyreflect larger, more aggressive cancers. Freedland acknowledges thatbecause PSA provides physicians with a measure of a patient's prostatehealth at a single point in time, it's "far from perfect." However, hesays, "it's better than anything else we have."

"As a screening tool, PSA has done what we wanted it to do," Freedlandsays. "It detects advanced disease early and reduces the likelihood ofmetastatic disease."

For the study, Freedland and colleagues reviewed patient records for 2,312men who had prostate removal surgery at Johns Hopkins between 1992 and2004. All operations were performed by Patrick C. Walsh, M.D., professorand former chair of urology. The research team compared the associationbetween preoperative PSA and the risk of cancer recurrence after surgery.

During an average follow-up of five years, 211 men (10 percent) had signsof recurrent cancer. Higher PSA levels prior to surgery were significantlyassociated with increased risk of cancer after surgery. Compared to menwith PSA levels less than 10 nanograms per milliliter, men with PSA valuesbetween 10 and 19.9 nanograms per milliliter were more than three timesmore likely to develop cancer after surgery. Men with PSA levels of 20nanograms per milliliter or greater were more than five times more likelyto develop cancer after surgery than those with low PSA levels.

Even in men with PSA values of less than 10 nanograms per milliliter,increasing PSA was significantly associated with increased risk of cancerafter surgery. For each two-point increase in PSA, the risk of cancer aftersurgery approximately doubled.

"From our study and others, it is clear that a single PSA value is anextremely useful measure of a patient's risk of progression after surgery,"Freedland says. "However, looking at how quickly the PSA increases overtime is likely to be even more informative than a single value."

###

The study was supported by the National Institutes of Health, theDepartment of Defense and the American Foundation for UrologicalDisease/American Urological Association.

Coauthors were Leslie A. Mangold and Walsh.

Links:
Brady Urological Institute at Johns Hopkins: http://urology.jhu.edu/
American Urological Association: http://www.auanet.org
Jhu_science_and_medicine_news mailing list:Jhu_science_and_medicine_news@resource2.ca.jhu.edu
http://resource2.ca.jhu.edu/mailman/listinfo/jhu_science_and_medicine_news


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "PSA Remains Best Indicator Of Prostate Cancer Progression." ScienceDaily. ScienceDaily, 18 September 2005. <www.sciencedaily.com/releases/2005/09/050918132628.htm>.
Johns Hopkins Medical Institutions. (2005, September 18). PSA Remains Best Indicator Of Prostate Cancer Progression. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2005/09/050918132628.htm
Johns Hopkins Medical Institutions. "PSA Remains Best Indicator Of Prostate Cancer Progression." ScienceDaily. www.sciencedaily.com/releases/2005/09/050918132628.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins